Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-mercaptopurine proof-of-concept trial in pulmonary arterial hypertension
NL-OMON45698Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mercaptopurine in pulmonary arterial hypertension (PAH), sponsored by Vrije University Medical Center. Primary endpoint: Change in pulmonary vascular resistance. Started Aug 2017; status: active, not recruiting.
02
Drugs
mercaptopurine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON45698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45698.